Skip to Content
Merck
CN

SML0521

ML 210

≥98% (HPLC), GPX4 inhibitor, powder

Synonym(s):

CID 49766530, ML-210, [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H20Cl2N4O4
CAS Number:
1360705-96-9
Molecular Weight:
475.32
UNSPSC Code:
12352200
PubChem Substance ID:
329825528
NACRES:
NA.77
MDL number:
MFCD22666407

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

ML 210, ≥98% (HPLC)

SMILES string

Cc1onc(C(=O)N2CCN(CC2)C(c3ccc(Cl)cc3)c4ccc(Cl)cc4)c1[N+]([O-])=O

InChI

1S/C22H20Cl2N4O4/c1-14-20(28(30)31)19(25-32-14)22(29)27-12-10-26(11-13-27)21(15-2-6-17(23)7-3-15)16-4-8-18(24)9-5-16/h2-9,21H,10-13H2,1H3

InChI key

VIBHJPDPEVVDTB-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

storage temp.

2-8°C

Quality Level

100

Related Categories

Application

ML 210 has been used as a glutathione peroxidase 4 (GPX4) inhibitor to induce ferroptosis in cancer cells. It has also been used as a GPX4 inhibitor to examine whether pharmacological inhibition of GPX4 altered prominin2 expression and impacted ferroptosis in adherent MCF10A and Hs578t cells.

Biochem/physiol Actions

ML 210 acts as a selenoenzyme glutathione peroxidase 4 (GPX4) inhibitor. It exhibits cytotoxicity against few ovarian cancer cell lines.
ML 210 induces cell death in RAS expressing tumor cells.
ML 210 induces non-apoptotic cell death in tumor cells expressing the RAS oncogene.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000455990
0000455987
0000455987
0000455990
0000382063

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Amrita Basu et al.
Cell, 154(5), 1151-1161 (2013-09-03)
The high rate of clinical response to protein-kinase-targeting drugs matched to cancer patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) profiling to identify additional biomarkers of small-molecule sensitivities. We have quantitatively measured the sensitivity
Matthew J Hangauer et al.
Nature, 551(7679), 247-250 (2017-11-02)
Acquired drug resistance prevents cancer therapies from achieving stable and complete responses. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells. The persister cell pool constitutes a reservoir from which
Leslie Magtanong et al.
Cell chemical biology, 29(9), 1409-1418 (2022-07-10)
Ferroptosis is an important mediator of pathophysiological cell death and an emerging target for cancer therapy. Whether ferroptosis sensitivity is governed by a single regulatory mechanism is unclear. Here, based on the integration of 24 published chemical genetic screens combined
Ji-Yoon Lee et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(51), 32433-32442 (2020-12-09)
Ferroptosis is an iron-dependent regulated necrosis mediated by lipid peroxidation. Cancer cells survive under metabolic stress conditions by altering lipid metabolism, which may alter their sensitivity to ferroptosis. However, the association between lipid metabolism and ferroptosis is not completely understood.
Yinu Wang et al.
Cancer research, 81(2), 384-399 (2020-11-12)
Defining traits of platinum-tolerant cancer cells could expose new treatment vulnerabilities. Here, new markers associated with platinum-tolerant cells and tumors were identified using in vitro and in vivo ovarian cancer models treated repetitively with carboplatin and validated in human specimens.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service